
Diabetes is a global public health problem. The global diabetes patients according to the statistics of the World Health Organization reach as high as 400 million. The diabetes incidence in many developing counties including China, etc. is far higher than the world average level. One in every ten people in China has diabetes, and this incidence is experiencing "explosive" growth, showing a very severe situation. The huge base of diabetes patients decides a huge diabetes drug market. There are countless companies and institutions conducting diabetes drug development, but statistical data show that the overall market becomes increasingly monopolized, in spite of the countless companies developing diabetes drugs and countless drug categories.
|
Ranking |
Company |
Main drug |
2016 sales/USD 100 million |
|
1 |
Novo Nordisk |
Insulin detemir, NovoRapid, insulin degludec, and liraglutide |
123.1 |
|
2 |
Sanofi |
Insulin glargine, and lixisenatide |
81.2 |
|
3 |
Merck |
Sitagliptin |
61.1 |
|
4 |
Eli Lilly |
Insulin lispro, and dulaglutide |
58.1 |
|
5 |
AstraZeneca |
Exenatide, and dapagliflozin |
23.9 |
Table I Top 5 pharmaceutical enterprises by 2016 diabetes drug sales
The top 5 pharmaceutical enterprises by 2016 global diabetes drug sales were separately Novo Nordisk, Sanofi, Merck, Eli Lilly and AstraZeneca, with total sales of more than USD 30 billion, occupying most of the diabetes drug market shares. The rankings of those companies have been high, and the places have hardly changed in recent years. Japan Takeda Pharmaceutical created USD 4.2 billion diabetes drug sales in 2011, ranking fourth in that year, but the sales of the company continued to decline thereafter, and from that year on, positions of top 5 pharmaceutical enterprises in diabetes drug market have not be shaken.









(All Rights Reserved)